



1276302-3corrected.ST25.txt
SEQUENCE LISTING

<110> Yeda Research and Development Company Ltd.
<120> ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW PEPTIDE
<130> 24390 (1276302)
<140> 09/647,457
<141> 2000-09-29
<150> PCT/IL99/00190
<151> 1999-09-29
<150> 123925
<151> 1998-04-02
<160> 15
<170> PatentIn version 3.2
<210> 1
<211> 28
<212> PRT
<213> Unknown
<220>
<223> being the immunologically active epitope

<220>
<221> MISC_FEATURE
<222> (1)..(11)
<223> Xaa(1) is S or absent; Xaa(2) is G or absent; Xaa(3) is E or absent; Xaa(4) is T or absent; Xaa(5) is E or absent; Xaa(6) is D or absent; Xaa(7) is T or absent; Xaa(8) is F or absent; Xaa(9) is I or absent; Xaa(10) is A or absent; provided that when Xaa(11) is absent, Xaa(1) through Xaa(10), inclusive, are absent, and when Xaa(11) is D, Xaa(10) is A or absent; when Xaa(10) is absent, Xaa(1) through Xaa(9), inclusive, are absent, and when Xaa(10) is A, Xaa(9) is I or absent; when Xaa(9) is absent, Xaa(1) through Xaa(8), inclusive, are absent, and when Xaa(9) is I, Xaa(8) is F or absent; when Xaa(8) is absent, Xaa(1) through Xaa(7), inclusive, are absent, and when Xaa(8) is F, Xaa(1) through Xaa(7) are, respectively, S, G, E, T, E, D, and T.

<220>
<221> MISC_FEATURE
<222> (12)..(28)
<223> Xaa(19) is C, G, P; Xaa(25) is A, P; Xaa(26) is P, A; Xaa(28) is R or absent, provided that Xaa(25) and Xaa(26) are taken together to form a sequence selected from the group consisting of AP and PA.

<400> 1
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Val Val Gly Leu
1 5 10 15

Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Xaa Cys Xaa
20 25

<210> 2
 <211> 28
 <212> PRT
 <213> Unknown

<220>
 <223> being the immunologically active epitope

<400> 2

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
 1 5 10 15

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
 20 25

<210> 3
 <211> 16
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 3

Leu val val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys
 1 5 10 15

<210> 4
 <211> 20
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients.

<400> 4

Ile Ala Asp Leu val val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly
 1 5 10 15

Ala Pro Cys Arg
 20

<210> 5
 <211> 19
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 5

Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala
1 5 10 15

Pro Cys Arg

<210> 6

<211> 18

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 6

Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
1 5 10 15

Cys Arg

<210> 7

<211> 17

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 7

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
1 5 10 15

Arg

<210> 8

<211> 17

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 8

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15

Arg

<210> 9
 <211> 17
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 9

Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
 1 5 10 15

Arg

<210> 10
 <211> 20
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 10

Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
 1 5 10 15

Cys Thr Gly Gln
 20

<210> 11
 <211> 16
 <212> PRT
 <213> Unknown

<220>
 <223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 11

Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
 1 5 10 15

<210> 12
 <211> 12
 <212> PRT
 <213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 12

Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
1 5 10

<210> 13

<211> 16

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 13

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys
1 5 10 15

<210> 14

<211> 15

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 14

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro
1 5 10 15

<210> 15

<211> 16

<212> PRT

<213> Unknown

<220>

<223> peptide capable of binding antibodies that are found in elevated levels in body fluids of schizophrenic patients

<400> 15

Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
1 5 10 15